Drugmaker Wins Tax Offset Ruling in California

A state tribunal sided with a biopharmaceutical company's use of research tax credits against its 2015 California alternative minimum tax.

Updated on Nov. 2, 2026 in Biotech

Drugmaker Wins Tax Offset Ruling in California

The California Office of Tax Appeals ruled that a biopharmaceutical company later acquired by Pfizer Inc. properly offset its 2015 California alternative minimum tax with research tax credits. The tribunal rejected the Franchise Tax Board's request to overturn the 15-year-old NASSCO precedent.

Why it matters

The decision reinforces a long-standing rule governing how corporations can apply credits against California's minimum tax obligations. Because the tribunal found the issue almost identical to NASSCO, the ruling keeps that precedent intact for taxpayers.

The appeal turned on whether research tax credits can offset California's corporate alternative minimum tax, the same question NASSCO answered for enterprise zone and manufacturer's investment credits. The stub does not disclose the dollar amount at issue or any further appeal by the Franchise Tax Board.

The players

Franchise Tax Board

California's state agency responsible for administering personal income and corporation tax laws, which asked the tribunal to overturn the NASSCO precedent.

California Office of Tax Appeals

The independent state tribunal that hears tax disputes between taxpayers and the Franchise Tax Board and issued the ruling.

Pfizer Inc.

The global pharmaceutical company that later acquired the biopharmaceutical drugmaker whose 2015 tax offset was at issue.

The details

The company applied research tax credits against its California alternative minimum tax liability for 2015. The Office of Tax Appeals found the issue almost identical to the one decided in In re NASSCO Holdings Inc., which the Board of Equalization decided and which allows a taxpayer to offset corporate AMT using certain credits. The decision was made public Monday.

2015: The drugmaker's California alternative minimum tax liability year, offset by research credits.
Monday, November 2, 2026: The tribunal's decision was made public, rejecting the Franchise Tax Board's request.

The Tech Race

The tribunal reaffirmed the NASSCO precedent, which the Board of Equalization set in the agency's predecessor body and which has governed corporate AMT offsets for 15 years. The decision extends that holding from enterprise zone and manufacturer's investment credits to research credits claimed by a biotech drugmaker.

Biopharmaceutical companies doing business in California may rely on research tax credits to reduce their state minimum tax liability under this precedent. The ruling affects how those companies calculate what they owe, though the stub does not quantify the effect on any specific taxpayer.

The takeaway

Corporate taxpayers in California can point to the NASSCO precedent when applying credits against the alternative minimum tax, and this ruling confirms that approach extends to research credits. Companies should review how their own credits interact with state minimum tax rules.